(Weisenthal's note #1: the reviewer's statistics relating to assay performance in the ovarian cancer studies are very misleading. Here are the actual findings in the studies quoted above; references given in a review of CCDRT in ovarian cancer presented elsewhere on this website):
Author
n Overall RR RR,"Sensitive"
RR,"Resistant" Ref (bold clickable)
Weisenthal 3
33% 100% 0%
[12]
Blackman 72
44% 72%
4% [31]
Carstensen 22
27% 60%
0%
[32]
Ng
20 31% 50%
0% [33]
Konecny 38
54% 66%
11% [34]
Ohie 15
53% 88%
14%
[35]
Sargent 25
42% 60% 10%
[36]
Sevin 31
81% 100%
25% [37]
Sevin
65 77%
94%
29%
[38]
Taylor 37
46% 65%
15%
[39]
O'Meara 161
65% 83%
43%
[40]
Taylor 120 (see linked
paper) [41]
Total N=609,see
text
Specificity
= 0.92 (Specificity for drug resistance)
Sensitivity
= 0.72 (Sensitivity for drug resistance)
Return to "the paper reviewed" (ONCOLOGY annonymous review):